















61. Nencioni A, Schwarzenberg K, Brauer KM, Schmidt SM, Ballestrero A, et al. (2006) Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. *Blood* 108: 551-558.
62. Miguel JFS, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, et al. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 359: 906-917.
63. Murakami-Satsutani N, Ito T, Nakanishi T, Inagaki N, Tanaka A, et al. (2014) IL-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of OX40 ligand. *Allergol Int* 63: 443-455.
64. Nakanishi T, Inaba M, Inagaki-Katashiba N, Tanaka A, Vien PT, et al. (2015) Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin. *Platelets* 26: 425-431.
65. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, et al. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366: 1782-1791.
66. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, et al. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. *N Engl J Med* 366: 1770-1781.